Chief Commercial Officer Eric Karas sold 10,000 shares of ARS Pharmaceuticals Inc (SPRY, Financial) on September 18, 2024, according to a recent SEC Filing. Following this transaction, the insider now owns 5,693 shares of the company.
ARS Pharmaceuticals Inc is engaged in the development of novel, non-opioid products for patients to manage their pain and inflammation. The company is known for its innovative approaches in the pharmaceutical sector.
Over the past year, Eric Karas has sold a total of 20,000 shares and has not purchased any shares. This recent transaction is part of a broader trend observed within the company, where insider sells have significantly outnumbered buys. In the past year, there have been 41 insider sells and only 3 insider buys.
Shares of ARS Pharmaceuticals Inc were trading at $14 on the day of the transaction. The company's market cap is approximately $1.44 billion.
For more detailed valuation metrics, such as the GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can visit the respective links.
This insider sell event may be of interest to current and potential investors trying to understand the recent activities within ARS Pharmaceuticals Inc and how insiders like Eric Karas are interacting with their holdings in the company.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
